Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice

Danielle Gulick, Thomas J. Gould

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Ethanol is a frequently abused drug that impairs cognitive processes such as learning. Varenicline, an α4β2 nicotinic receptor partial agonist and α7 nicotinic receptor full agonist prescribed for smoking cessation, has been shown to decrease ethanol consumption. The current study investigated whether varenicline could ameliorate ethanol-induced deficits in learning and whether varenicline alters blood alcohol concentration in C57BL/6 mice. Conditioning consisted of two auditory conditioned stimulus (CS; 30 s, 85 dB white noise)-foot shock unconditioned stimulus (US; 2 s, 0.57 mA) pairings. For all studies, saline or ethanol (1.0, 1.5, 2.0 g/kg i.p.) was administered 15 min before training, and saline or varenicline (0.05, 0.1, 0.2 mg/kg i.p.) was administered 60 min before either training or testing. For blood alcohol analysis, saline or varenicline (0.1 mg/kg) was administered 60 min before collection, and saline or ethanol (1.0, 1.5, 2.0 g/kg) was administered 15 min before collection. Varenicline dose-dependently ameliorated ethanol-induced conditioning deficits for all three doses of ethanol when administered before training but not when administered 24 h later, before testing. In addition, varenicline did not alter blood alcohol concentration. The smoking cessation aid varenicline may have therapeutic uses for treating ethanol-associated disruptions in cognitive processes.

Original languageEnglish (US)
Pages (from-to)230-236
Number of pages7
JournalNeurobiology of Learning and Memory
Volume90
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

Inbred C57BL Mouse
Ethanol
Learning
Nicotinic Receptors
Smoking Cessation
Varenicline
Therapeutic Uses
Foot
Shock
Alcohols
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Experimental and Cognitive Psychology
  • Cognitive Neuroscience
  • Behavioral Neuroscience

Cite this

@article{481a00a24d1c4b22add2f6cca176d1f2,
title = "Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice",
abstract = "Ethanol is a frequently abused drug that impairs cognitive processes such as learning. Varenicline, an α4β2 nicotinic receptor partial agonist and α7 nicotinic receptor full agonist prescribed for smoking cessation, has been shown to decrease ethanol consumption. The current study investigated whether varenicline could ameliorate ethanol-induced deficits in learning and whether varenicline alters blood alcohol concentration in C57BL/6 mice. Conditioning consisted of two auditory conditioned stimulus (CS; 30 s, 85 dB white noise)-foot shock unconditioned stimulus (US; 2 s, 0.57 mA) pairings. For all studies, saline or ethanol (1.0, 1.5, 2.0 g/kg i.p.) was administered 15 min before training, and saline or varenicline (0.05, 0.1, 0.2 mg/kg i.p.) was administered 60 min before either training or testing. For blood alcohol analysis, saline or varenicline (0.1 mg/kg) was administered 60 min before collection, and saline or ethanol (1.0, 1.5, 2.0 g/kg) was administered 15 min before collection. Varenicline dose-dependently ameliorated ethanol-induced conditioning deficits for all three doses of ethanol when administered before training but not when administered 24 h later, before testing. In addition, varenicline did not alter blood alcohol concentration. The smoking cessation aid varenicline may have therapeutic uses for treating ethanol-associated disruptions in cognitive processes.",
author = "Danielle Gulick and Gould, {Thomas J.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.nlm.2008.03.002",
language = "English (US)",
volume = "90",
pages = "230--236",
journal = "Neurobiology of Learning and Memory",
issn = "1074-7427",
publisher = "Academic Press Inc.",
number = "1",

}

Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice. / Gulick, Danielle; Gould, Thomas J.

In: Neurobiology of Learning and Memory, Vol. 90, No. 1, 01.07.2008, p. 230-236.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice

AU - Gulick, Danielle

AU - Gould, Thomas J.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Ethanol is a frequently abused drug that impairs cognitive processes such as learning. Varenicline, an α4β2 nicotinic receptor partial agonist and α7 nicotinic receptor full agonist prescribed for smoking cessation, has been shown to decrease ethanol consumption. The current study investigated whether varenicline could ameliorate ethanol-induced deficits in learning and whether varenicline alters blood alcohol concentration in C57BL/6 mice. Conditioning consisted of two auditory conditioned stimulus (CS; 30 s, 85 dB white noise)-foot shock unconditioned stimulus (US; 2 s, 0.57 mA) pairings. For all studies, saline or ethanol (1.0, 1.5, 2.0 g/kg i.p.) was administered 15 min before training, and saline or varenicline (0.05, 0.1, 0.2 mg/kg i.p.) was administered 60 min before either training or testing. For blood alcohol analysis, saline or varenicline (0.1 mg/kg) was administered 60 min before collection, and saline or ethanol (1.0, 1.5, 2.0 g/kg) was administered 15 min before collection. Varenicline dose-dependently ameliorated ethanol-induced conditioning deficits for all three doses of ethanol when administered before training but not when administered 24 h later, before testing. In addition, varenicline did not alter blood alcohol concentration. The smoking cessation aid varenicline may have therapeutic uses for treating ethanol-associated disruptions in cognitive processes.

AB - Ethanol is a frequently abused drug that impairs cognitive processes such as learning. Varenicline, an α4β2 nicotinic receptor partial agonist and α7 nicotinic receptor full agonist prescribed for smoking cessation, has been shown to decrease ethanol consumption. The current study investigated whether varenicline could ameliorate ethanol-induced deficits in learning and whether varenicline alters blood alcohol concentration in C57BL/6 mice. Conditioning consisted of two auditory conditioned stimulus (CS; 30 s, 85 dB white noise)-foot shock unconditioned stimulus (US; 2 s, 0.57 mA) pairings. For all studies, saline or ethanol (1.0, 1.5, 2.0 g/kg i.p.) was administered 15 min before training, and saline or varenicline (0.05, 0.1, 0.2 mg/kg i.p.) was administered 60 min before either training or testing. For blood alcohol analysis, saline or varenicline (0.1 mg/kg) was administered 60 min before collection, and saline or ethanol (1.0, 1.5, 2.0 g/kg) was administered 15 min before collection. Varenicline dose-dependently ameliorated ethanol-induced conditioning deficits for all three doses of ethanol when administered before training but not when administered 24 h later, before testing. In addition, varenicline did not alter blood alcohol concentration. The smoking cessation aid varenicline may have therapeutic uses for treating ethanol-associated disruptions in cognitive processes.

UR - http://www.scopus.com/inward/record.url?scp=44649091159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649091159&partnerID=8YFLogxK

U2 - 10.1016/j.nlm.2008.03.002

DO - 10.1016/j.nlm.2008.03.002

M3 - Article

C2 - 18411066

AN - SCOPUS:44649091159

VL - 90

SP - 230

EP - 236

JO - Neurobiology of Learning and Memory

JF - Neurobiology of Learning and Memory

SN - 1074-7427

IS - 1

ER -